Table 1.
Baseline characteristics of studied population.
| Studied population N = 414 | SC-group N = 95 | STM-group N = 99 | ITM-group N = 220 | P-value | |
|---|---|---|---|---|---|
| Age | 63.45 ± 13.98 | 66.24 ± 13.20 | 66.57 ± 12.78 | 60.84 ± 14.36 | <0.05 |
| Male sex | 328 (79.2%) | 75 (78.9%) | 79 (79.8%) | 174 (79.1%) | 0.987 |
| BMI (kg/m2) | 26.92 ± 5.37 | 27.12 ± 5.54 | 26.90 ± 5.02 | 26.84 ± 5.47 | 0.917 |
| Hypertension | 170 (41.6%) | 46 (48.4%) | 48 (48.5%) | 76 (35.3%) | 0.027 |
| Diabetes mellitus | 108 (26.4%) | 35 (36.8%) | 31 (31.3%) | 42 (19.5%) | 0.03 |
| Heart transplant | 30 (7.2%) | 6 (6.3%) | 10 (10.1) | 14 (6.4%) | 0.454 |
| Ambulatory | 37 (8.9%) | 1 (1.1%) | 3 (3.0%) | 33 (15.0%) | <0.05 |
| Ischemic HF | 171 (41.4%) | 47 (50.0%) | 46 (46.5%) | 78 (35.4%) | 0.028 |
| LVEF (%) | 30.21 ± 11.97 | 31.43 ± 12.79 | 33.33 ± 13.62 | 28.28 ± 10.40 | 0.005 |
| NTproBNP (pg/ml) | 6010 ± 8398 | 6205 ± 7588 | 7141 ± 11279 | 5522 ± 7367 | 0.932 |
| Beta-blocker | 340 (83.1%) | 77 (81.1%) | 76 (76.8%) | 187 (87%) | 0.067 |
| (ACEi, ARB, ARNIs) | 334 (81.7%) | 74 (77.9%) | 71 (71.7%) | 189 (87.9%) | 0.001 |
| Furosemide | 399 (96.4%) | 90 (94.7%) | 94 (94.9%) | 215 (97.7%) | 0.248 |
| Ivabradine | 48 (11.7%) | 9 (9.5%) | 4 (4.0%) | 35 (16.3%) | 0.005 |
SC-group, standard of care group; STM-group, standard telemonitoring-group; ITM-group, interventional telemonitoring group; BMI, body mass index; HF, heart failure; LVEF, left ventricular ejection fraction; ACEi, Angiotensin converting enzyme inhibitor; ARB, Angiotensinogen 2 receptor antogaonist; ARNIs, Angiotensin receptor-neprilysin inhibitors.